JP2016138129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016138129A5 JP2016138129A5 JP2016078639A JP2016078639A JP2016138129A5 JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5 JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fcγriib
- composition
- target cell
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1013989.7A GB201013989D0 (en) | 2010-08-20 | 2010-08-20 | Biological materials and methods of using the same |
| GB1013989.7 | 2010-08-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Division JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016138129A JP2016138129A (ja) | 2016-08-04 |
| JP2016138129A5 true JP2016138129A5 (enExample) | 2017-06-08 |
| JP6421140B2 JP6421140B2 (ja) | 2018-11-07 |
Family
ID=42984443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
| JP2016078639A Active JP6421140B2 (ja) | 2010-08-20 | 2016-04-11 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10525129B2 (enExample) |
| EP (2) | EP2606068B1 (enExample) |
| JP (2) | JP6215704B2 (enExample) |
| KR (1) | KR101948609B1 (enExample) |
| CN (8) | CN107670034B (enExample) |
| AU (1) | AU2011290503B2 (enExample) |
| CA (1) | CA2808744C (enExample) |
| DK (1) | DK2606068T3 (enExample) |
| ES (1) | ES2653685T3 (enExample) |
| GB (1) | GB201013989D0 (enExample) |
| HU (1) | HUE037478T2 (enExample) |
| NO (1) | NO2606068T3 (enExample) |
| PL (1) | PL2606068T3 (enExample) |
| PT (1) | PT2606068T (enExample) |
| RU (2) | RU2769949C2 (enExample) |
| SI (1) | SI2606068T1 (enExample) |
| WO (1) | WO2012022985A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| WO2014085596A1 (en) * | 2012-11-29 | 2014-06-05 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC) |
| EP2740805B1 (en) * | 2012-12-07 | 2019-02-20 | SuppreMol GmbH | Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura |
| EP3666795A1 (en) | 2013-03-12 | 2020-06-17 | Molecular Templates, Inc. | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| CN112851769A (zh) | 2014-01-27 | 2021-05-28 | 分子模板公司 | 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| CN106604934A (zh) | 2014-06-11 | 2017-04-26 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| EP3253799B1 (en) | 2015-02-05 | 2020-12-02 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| WO2016146702A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| RU2018126297A (ru) | 2015-12-18 | 2020-01-22 | Новартис Аг | Антитела, нацеленные на cd32b, и способы их применения |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018106895A1 (en) | 2016-12-07 | 2018-06-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| MX2019008840A (es) | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
| US11459378B2 (en) | 2017-01-30 | 2022-10-04 | Ohio State Innovation Foundation | Passive antibody dependent cell-mediated activation |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| CN110612117B (zh) | 2018-04-17 | 2024-04-12 | 分子模板公司 | 包含去免疫化的志贺毒素a亚基支架的her2靶向分子 |
| CN108823211A (zh) * | 2018-05-04 | 2018-11-16 | 中国医学科学院基础医学研究所 | 一种cd19核酸适配体及其应用 |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| US20220259309A1 (en) * | 2019-07-17 | 2022-08-18 | Bioinvent International Ab | Antibody combinations for treatment of cancer in specific patients |
| WO2021076196A1 (en) * | 2019-10-18 | 2021-04-22 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021245238A1 (en) | 2020-06-04 | 2021-12-09 | Bioinvent International Ab | Improving antibody tolerability associated with intravenous administration |
| EP3919077A1 (en) | 2020-06-04 | 2021-12-08 | BioInvent International AB | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| US20230399375A1 (en) | 2022-04-15 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2390412A1 (en) * | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| DK1534335T4 (en) * | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| AU2003265522A1 (en) * | 2003-08-18 | 2005-03-10 | Macrogenics, Inc. | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| NZ547629A (en) | 2003-11-26 | 2009-08-28 | Max Planck Gesellschaft | Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| JP5367982B2 (ja) | 2004-04-16 | 2013-12-11 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| CA2565874C (en) * | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| WO2006048781A2 (en) * | 2004-05-20 | 2006-05-11 | St. Mary's Hospital Nhs Trust | IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| WO2006066078A2 (en) * | 2004-12-15 | 2006-06-22 | Magrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| WO2008002933A2 (en) * | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2009062051A2 (en) * | 2007-11-08 | 2009-05-14 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| WO2009083009A2 (en) * | 2008-01-03 | 2009-07-09 | Genmab A/S | Monoclonal antibodies against cd32b |
| WO2010080994A2 (en) | 2009-01-08 | 2010-07-15 | The Uab Research Foundation | Process for regulating immune response |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
-
2010
- 2010-08-20 GB GBGB1013989.7A patent/GB201013989D0/en not_active Ceased
-
2011
- 2011-08-19 CN CN201710789909.3A patent/CN107670034B/zh active Active
- 2011-08-19 ES ES11760819.0T patent/ES2653685T3/es active Active
- 2011-08-19 CN CN202511469650.5A patent/CN121313820A/zh active Pending
- 2011-08-19 US US13/817,744 patent/US10525129B2/en active Active
- 2011-08-19 CA CA2808744A patent/CA2808744C/en active Active
- 2011-08-19 PT PT117608190T patent/PT2606068T/pt unknown
- 2011-08-19 DK DK11760819.0T patent/DK2606068T3/da active
- 2011-08-19 CN CN201180040351XA patent/CN103080131A/zh active Pending
- 2011-08-19 SI SI201131366T patent/SI2606068T1/en unknown
- 2011-08-19 CN CN202110959481.9A patent/CN114099669A/zh active Pending
- 2011-08-19 NO NO11760819A patent/NO2606068T3/no unknown
- 2011-08-19 KR KR1020137006990A patent/KR101948609B1/ko active Active
- 2011-08-19 CN CN202110959352.XA patent/CN114099666B/zh active Active
- 2011-08-19 RU RU2017143633A patent/RU2769949C2/ru active
- 2011-08-19 EP EP11760819.0A patent/EP2606068B1/en active Active
- 2011-08-19 WO PCT/GB2011/051572 patent/WO2012022985A1/en not_active Ceased
- 2011-08-19 CN CN202110959355.3A patent/CN114099702B/zh active Active
- 2011-08-19 EP EP17184259.4A patent/EP3263602A1/en not_active Withdrawn
- 2011-08-19 HU HUE11760819A patent/HUE037478T2/hu unknown
- 2011-08-19 JP JP2013524483A patent/JP6215704B2/ja active Active
- 2011-08-19 CN CN202110959354.9A patent/CN114099668B/zh active Active
- 2011-08-19 AU AU2011290503A patent/AU2011290503B2/en active Active
- 2011-08-19 CN CN202110959353.4A patent/CN114099667B/zh active Active
- 2011-08-19 PL PL11760819T patent/PL2606068T3/pl unknown
- 2011-08-19 RU RU2013112345/10A patent/RU2013112345A/ru unknown
-
2016
- 2016-04-11 JP JP2016078639A patent/JP6421140B2/ja active Active
-
2019
- 2019-11-14 US US16/684,450 patent/US11623005B2/en active Active
-
2021
- 2021-06-25 US US17/359,496 patent/US20210346498A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/177,050 patent/US12527866B2/en active Active
-
2025
- 2025-12-16 US US19/421,037 patent/US20260115286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016138129A5 (enExample) | ||
| RU2017143633A (ru) | Биологические материалы и способы их применения | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2018518540A5 (enExample) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2023506184A5 (enExample) | ||
| JP2019507762A5 (enExample) | ||
| KR20140014064A (ko) | 신규한 조절 인자 및 사용 방법 | |
| JP2015172045A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2019505564A5 (enExample) | ||
| JP2022527151A5 (enExample) | ||
| JP2013519375A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| KR20140018837A (ko) | 노텀 단백질 조절 인자 및 사용 방법 | |
| JP2020500510A5 (enExample) | ||
| US10035848B2 (en) | Antibody targeting cell surface deposited complement protein C3d and use thereof | |
| JP2022514734A5 (enExample) | ||
| JP2021529776A5 (enExample) | ||
| JP2016529213A5 (enExample) | ||
| WO2021126672A1 (en) | Compositions and methods of treating cancer with chimeric antigen receptors targeting glypican 3 | |
| JP2025512953A5 (enExample) | ||
| JP2020515286A5 (enExample) |